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Abstract ADAMTS4 (aggrecanase-1) is considered to play a
key role in the degradation of aggrecan in arthritides. The
inhibitory activity of tissue inhibitors of metalloproteinases
(TIMPs) to ADAMTS4 was examined in an assay using
aggrecan substrate. Among the four TIMPs, TIMP-3 inhibited
the activity most efficiently with an IC50 value of 7.9 nM, which
was at least 44-fold lower than that of TIMP-1 (350 nM) and
TIMP-2 (420 nM) and s 250-fold less than that of TIMP-4 (2
WM for 35% inhibition). These results suggest that TIMP-3 is a
potent inhibitor against the aggrecanase activity of ADAMTS4
in vivo. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
ADAM (a disintegrin and metalloproteinase) is a recently
discovered gene family, and involved in various biological
events including fertilization [1,2], myogenesis [3], cytokine
shedding [4,5] and extracellular matrix (ECM) degradation
[6^8] under pathophysiological conditions. The members can
be classi¢ed into two groups according to their domain struc-
tures: membrane type ADAM and ADAM with thrombo-
spondin motifs (ADAMTS) [9]. Among 10 members of the
ADAMTS subgroup, ADAMTS4, also called aggrecanase-1,
is notable in that it cleaves aggrecan, a major proteoglycan in
cartilage, at the ¢ve speci¢c sites of the core protein including
the Glu373^Ala374 bond in the G1^G2 interglobular domain
[8]. Because of the expression and aggrecanase activity of the
proteinase, ADAMTS4 is believed to play a key role in the
destruction of articular cartilage through aggrecan degrada-
tion in human arthritides such as rheumatoid arthritis and
osteoarthritis [10^12]. However, no information is available
for the regulators of the aggrecanase activity of ADAMTS4
in vivo. Tissue inhibitors of metalloproteinases composed of
four di¡erent molecules (TIMP-1, 2, 3 and 4) were originally
cloned as inhibitors of matrix metalloproteinases (MMPs)
[13], but recent studies have shown that TIMP-1 weakly in-
hibits the activity of ADAMTS4 [6,7]. However, little is
known about the inhibitory activity of other TIMPs, i.e.
TIMP-2, 3 and 4, to the proteinase.
In the present study, we examined the inhibitory activity of
TIMP-1, 2, 3 and 4 against the puri¢ed recombinant human
ADAMTS4. The data demonstrate that TIMP-3 most e⁄-
ciently inhibits the aggrecanase activity of ADAMTS4 among
the four TIMPs.
2. Materials and methods
2.1. Materials
Recombinant human TIMP-1 and TIMP-2 were puri¢ed as de-
scribed previously [14]. Human TIMP-3 was also puri¢ed from pla-
centas with ion-exchange and immunoa⁄nity column chromatogra-
phy by modi¢cation of the method described by Apte et al. [15].
Mouse TIMP-4, which is 93% identical to human TIMP-4, was iso-
lated from Escherichia coli [16] and provided by Dr. Vera Kna«uper
and Dr. Gillian Murphy (University of East Anglia, Norwich, UK). A
polyclonal antibody (I19C) speci¢c to the neo-epitope (NITEGE373)
of the V80 kDa aggrecan fragment generated by the cleavage at the
Glu373^Ala374 bond with ADAMTS4 was prepared as described pre-
viously [17].
2.2. Puri¢cation of recombinant ADAMTS4
Recombinant human ADAMTS4 was puri¢ed according to our
method [18]. Brie£y, ADAMTS4 expression vector with the FLAG
epitope tag added to the COOH-terminus was transfected into COS-7
cells. The culture media were harvested 3 days after the transfection,
concentrated by ultra¢ltration and subjected to anti-FLAG M2 a⁄n-
ity column chromatography (Sigma-Aldrich Corp., St. Louis, MO,
USA). Recombinant ADAMTS4 was eluted with 6 M urea, dialyzed
against 50 mM Tris^HCl (pH 7.5), 0.15 M NaCl, 10 mM CaCl2,
0.05% Brij-35 (TNCB bu¡er) and stored at 4‡C before use. The pu-
ri¢ed ADAMTS4 showed a single band of 69 kDa on the silver-
stained gel after sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE). Concentration of the proteinase was deter-
mined using BCA protein assay reagents (Pierce Chemical Co., Rock-
ford, IL, USA).
2.3. Aggrecan preparation
Bovine nasal cartilage (V10 g) was sliced and homogenized in 140
ml of 4 M guanidine^HCl in 50 mM sodium acetate (pH 5.8) con-
taining proteinase inhibitors cocktail (Complete, Roche Diagnostics,
Mannheim, Germany). Aggrecan was extracted from the cartilage for
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36 h at 20‡C, and isolated by cesium chloride (1.56 mg/ml) density-
gradient centrifugation at 100 000Ug for 48 h at 20‡C. Puri¢ed ag-
grecan was dialyzed against water, lyophilized and stored at 320‡C.
2.4. Detection of aggrecanase activity and its inhibition by TIMPs
Aggrecan (100 Wg) was ¢rst incubated with ADAMTS4 (4, 8, 16 or
32 nM at a ¢nal concentration) in TNCB bu¡er for 24 h at 37‡C. The
digestion products were treated with 0.025 units of chondroitinase
ABC and 0.01 unit of keratanase (Seikagaku Corp., Tokyo, Japan)
and subjected to SDS^PAGE (8 or 10% total acrylamide) under re-
ducing condition. The gels were stained with 0.1% Coomassie brilliant
blue R-250 (CBB) or silver nitrate. The proteins in the gels were also
transferred onto nitrocellulose ¢lters, and the digestion fragment by
ADAMTS4 was detected by the I19C antibody according to the avi-
din-biotin-peroxidase complex method [17]. Time course digestion of
aggrecan (100 Wg) was performed by incubation with ADAMTS4
(8 nM at a ¢nal concentration) for 0^24 h, and the appropriate in-
cubation time was determined.
For the inhibitor study with TIMPs, ADAMTS4 (8 nM) was in-
cubated with TIMP-1, 2, 3 or 4 (1, 5, 10, 50, 100, 250, 500 or 1000 nM
at a ¢nal concentration) for 2 h at 37‡C before the assay. Aggrecan
was then digested with the mixtures of ADAMTS4 and each TIMP
for 8 or 12 h at 37‡C, and the reaction was stopped with 20 mM
EDTA. The samples were subjected to SDS^PAGE (10% total acryl-
amide) under reducing condition after deglycosylation, and the pro-
teins transferred onto nitrocellulose ¢lters. The digestion fragment of
V80 kDa was detected by the neo-epitope speci¢c antibody (I19C) as
described above. They were also applied to SDS^PAGE (5% total
acrylamide) to observe the processing of the intact aggrecan core
protein into the V250-kDa fragment, and the gels stained with
0.1% CBB. Densities of immunoreactive bands with I19C antibody
and CBB-stained intact aggrecan core protein were measured by scan-
ning densitometry using NIH Image 1.62.
3. Results
When aggrecan (100 Wg) was fully digested with a high
concentration of ADAMTS4 (32 nM) for 24 h, aggrecan
core protein was processed into the two major fragments of
V250 kDa and V120 kDa (Fig. 1, lane 2). A minor fragment
of V80 kDa was recognized after silver staining (data not
shown), and detected by the I19C antibody (Fig. 2A), which
reacts with the neo-epitope (NITEGE373) of the fragment gen-
erated by cleavage at the Glu373^Ala374 bond [17]. To deter-
mine the appropriate incubation time for the inhibition study
with TIMPs, aggrecan (100 Wg) was incubated with
ADAMTS4 (8 nM) for various times ranging from 0 to 24
h, and the speci¢c band ofV80 kDa immunoreactive with the
I19C antibody was monitored by densitometry. As shown in
Fig. 2A, the band appeared after a 2-h incubation. Densito-
metric analysis indicated that the intensity of the band in-
creases linearly with time up to 12 h and then reached a
plateau after a 24-h incubation (Fig. 2B).
Inhibition activity of TIMP-1, 2, 3 and 4 against the aggre-
can-degrading activity of ADAMTS4 was measured by the
densitometric analysis of the immunoreactive band of V80
kDa after the digestion of aggrecan (100 Wg) with ADAMTS4
(8 nM) in the presence of TIMPs (0, 1, 5, 10, 50, 100, 250, 500
or 1000 nM). As shown in Fig. 3A, all the TIMPs except for
TIMP-4 completely inhibited the generation of the band at
di¡erent concentrations: 500, 1000 and 100 nM for TIMP-1,
2 and 3, respectively. In contrast, the complete inhibition was
not obtained with 1000 nM TIMP-4 (Fig. 3A) or even at a
Fig. 1. Aggrecan degradation by ADAMTS4. Aggrecan (100 Wg)
was incubated in the presence and absence of ADAMTS4 (32 nM)
for 24 h, and the digestion products were analyzed by SDS^PAGE
(8% total acrylamide) after the deglycosylation with chondroitinase
ABC and keratanase. Lane 1, aggrecan incubated with bu¡er alone
and deglycosylated; lane 2, aggrecan digested with ADAMTS4 and
deglycosylated; lane 3, chondroitinase ABC and keratanase alone.
Arrowhead and arrows indicate intact aggrecan core protein and
fragments of V250 kDa and V120 kDa, respectively.
Fig. 2. Time course digestion of aggrecan by ADAMTS4. Aliquots
of aggrecan (100 Wg) were incubated with ADAMTS4 (8 nM) for
0 (lane 1), 15 min (lane 2), 30 min (lane 3), 1 h (lane 4), 2 h (lane 5),
4 h (lane 6), 8 h (lane 7), 12 h (lane 8) or 24 h (lane 9), and the di-
gestion products were analyzed by immunoblotting using a neo-epi-
tope speci¢c antibody as described in Section 2. A: Immunoblotting
of the digestion products. B: Densitometric analysis of immunoreac-
tive fragments.
Fig. 3. Analysis of the inhibitory activity of TIMPs by immunoblot-
ting. Aliquots of aggrecan (100 Wg) were incubated with mixtures of
ADAMTS4 (8 nM) and various concentrations of TIMP-1, 2, 3 or
4 for 12 h, and the digestion products were analyzed by immuno-
blotting with an antibody as described in Section 2. A: Immuno-
blotting of the digestion products. Lanes 1^9, aggrecan digested
with the mixtures of ADAMTS4 and each TIMP (0, 1, 5, 10, 50,
100, 250, 500 and 1000 nM, respectively). B: Densitometric analysis
of the immunoreactive bands. The percent inhibition (mean of the
duplicate experiments) of ADAMTS4 activity with TIMP-1 (b),
TIMP-2 (a), TIMP-3 (F) or TIMP-4 (E) is plotted.
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concentration of 2000 nM (data not shown). When the data
measured by the densitometric analysis were plotted, S-shaped
inhibition curves were obtained for TIMP-1, 2 and 3 (Fig.
3B). Based on the curves, IC50 values (concentration at 50%
inhibition) were determined to be 350, 420 and 7.9 nM for
TIMP-1, 2 and 3, respectively. On the other hand, IC50 for
TIMP-4 could not be obtained, since 1000 and 2000 nM
TIMP-4 inhibited only 20 and 35% of the activity, respectively
(Fig. 3A for 1000 nM TIMP-4 and data not shown for 2000
nM TIMP-4). When inhibition of the processing of the intact
aggrecan core protein by TIMPs was monitored, very similar
inhibitor pro¢le was obtained. Almost complete inhibition
was seen at the concentrations of 500, 500 and 100 nM of
TIMP-1, 2 and 3, respectively, but only weak inhibition was
detected with TIMP-4 (Fig. 4A). IC50 values were roughly
calculated as 300, 400 and 18 nM for TIMP-1, 2 and 3, re-
spectively (Fig. 4B). However, they appeared not to be accu-
rate compared with those obtained by the analysis of the
V80-kDa immunoreactive band, since the di¡erence with
the densities of the intact core protein was subtle.
4. Discussion
We have demonstrated that the aggrecanase activity of
ADAMTS4 is inhibited by TIMPs. Previous studies have
shown that TIMP-1 weakly inhibits aggrecanase activity of
ADAMTS4 with an IC50 value of 210 nM [6,7]. Since this
value is close to that obtained in the present study (350 nM
for TIMP-1), our study con¢rms the data. However, the
present study further showed that TIMP-2 is also capable to
inhibiting ADAMTS4 with a similar IC50 value (420 nM) to
that of TIMP-1. This is di¡erent from the previous data which
suggested that ADAMTS4 was insensitive to TIMP-2 at con-
centrations up to 1 WM [6]. Although the reason for the dis-
crepancy is not clear, this may be because in the previous
study culture media containing the proteinase were used for
the experiment [6]. On the other hand, the present study has
demonstrated for the ¢rst time that TIMP-3 most e⁄ciently
inhibits the aggrecanase activity of ADAMTS4. Judging from
its IC50 value (7.9 nM), the inhibitory activity of TIMP-3 is
about 50-fold higher than TIMP-1 and TIMP-2, and s 250-
fold stronger than TIMP-4. This suggests that TIMP-3 is a
potent inhibitor of ADAMTS4.
The molecular mechanism of the preferable inhibition of
ADAMTS4 by TIMP-3 is not apparent at present. However,
recent biochemical studies have indicated that TIMP-3 can
inhibit the activities of membrane-type ADAMs including
ADAM-10, ADAM-12 and ADAM-17 (TNF K converting
enzyme (TACE)) [16,19,20]. Thus, it is reasonable to think
that TIMP-3 has some structural features that are critical to
the inhibition of the activities of ADAM members, although
the key structural element remains unknown. On the other
hand, one of the most interesting characters of TIMP-3 is
that the N-terminal domain has binding a⁄nity to sulfated
glycosaminoglycans [21]. This character may be suitable for
TIMP-3 to be well-positioned to the cell surface through the
interaction with cell membrane heparan sulfate proteoglycans
such as syndecans [22] and to inhibit the membrane-type
ADAMs responsible for the shedding of the membrane pro-
teins. Since aggrecan is endowed with a large amount of chon-
droitin sulfate glycosaminoglycans, it is conceivable that the
sulfated chains may also be involved in the e⁄cient inhibitory
activity of TIMP-3 to ADAMTS4 through the interference
with the access of the proteinase to aggrecan.
The previous studies have demonstrated that the aggrecan
fragments generated by the action of ADAMTS4 are com-
monly detected in the joint £uids in rheumatoid arthritis
and osteoarthritis [23] and ADAMTS4 is expressed by the
chondrocytes in the diseased cartilages [24], suggesting that
this metalloproteinase plays an important role in the cartilage
destruction in such joint diseases [13]. Thus, endogenous in-
hibitor(s) of ADAMTS4 would be one of the key regulators
to prevent the cartilage destruction. Since the present data
suggest that of the four TIMPs, TIMP-3 is a potent inhibitor
in vivo, the up-regulation of TIMP-3 production may be ben-
e¢cial to the retardation of joint destruction in arthritides. We
have recently reported that TIMP-3 is expressed by rheuma-
toid synovial lining cells and its production is enhanced at the
post-transcriptional level by the treatment with calcium pen-
tosan polysulfate (CaPPS), an anti-arthritic agent [25]. CaPPS
is also known to inhibit loss of glycosaminoglycans from ar-
ticular cartilage in the explant cultures [26], and it increases
TIMP-3 production in osteoarthritic chondrocytes (Takizawa
et al., unpublished data). Thus, these data suggest the possi-
bility of the introduction of a new chondroprotective therapy
in human joint diseases by increasing the TIMP-3 levels in the
local joint tissues such as articular cartilage.
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